sramila aithal, md | neratinib and dose escalation | optimizing therapy for her2 disease
Published 3 years ago • 124 plays • Length 8:47Download video MP4
Download video MP3
Similar videos
-
3:56
sayeh lavasani, md, ms | neratinib and dose escalation | optimizing therapy for her2 disease
-
9:48
francis arena, md | neratinib and dose escalation | optimizing therapy for her2 disease
-
6:46
yifan tu, md | neratinib and dose escalation | optimizing therapy for her2 disease
-
1:07:43
new & supporting data for optimizing therapy in her2 breast cancer | dr. mahtani & dr. schwartzberg
-
1:45
antibody drug conjugates in metastatic breast cancer | sramila aithal, md | esmo22 pennsylvania
-
1:45
dr. sramila aithal describes the herceptin adjuvant (hera) trial for her2-positive breast cancer
-
1:03:44
new & supporting data for optimizing therapy in her2 breast cancer | dr. meisel & dr. soliman
-
3:11
neratinib prophylaxis in her2 metastatic breast cancer
-
33:34
sharing my her2 breast cancer diagnosis story at 35 years old
-
5:05
anti-her2 mechanisms of approved her2 inhibitors
-
20:11
her2-positive breast cancer—reduce your risk of recurrence | access health
-
1:19
asco22 metastatic breast cancer updates | sramila aithal, md | us oncology
-
8:12
her2 breast cancer: neratinib’s role as adjuvant therapy
-
5:21
study of neratinib for patients with her2-positive breast cancer with brain metastases
-
2:18
use of neratinib in her2-positive breast cancer
-
9:35
neratinib in her2 breast cancer
-
1:53
optimal timing for neratinib
-
4:09
her2 breast cancer: neratinib patient selection
-
4:54
patient selection for neratinib
-
0:52
dr. gradishar on the role of neratinib in the treatment of her2 breast cancer
-
8:33
pending fda approval of neratinib in her2 breast cancer
-
3:15
neratinib for metastatic breast cancer